Skip to main content
Erschienen in: Clinical Autonomic Research 4/2023

11.05.2023 | Review Article

Autonomic control of ventricular function in health and disease: current state of the art

verfasst von: Valerie Y. H. van Weperen, Crystal M. Ripplinger, Marmar Vaseghi

Erschienen in: Clinical Autonomic Research | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cardiac autonomic dysfunction is one of the main pillars of cardiovascular pathophysiology. The purpose of this review is to provide an overview of the current state of the art on the pathological remodeling that occurs within the autonomic nervous system with cardiac injury and available neuromodulatory therapies for autonomic dysfunction in heart failure.

Methods

Data from peer-reviewed publications on autonomic function in health and after cardiac injury are reviewed. The role of and evidence behind various neuromodulatory therapies both in preclinical investigation and in-use in clinical practice are summarized.

Results

A harmonic interplay between the heart and the autonomic nervous system exists at multiple levels of the neuraxis. This interplay becomes disrupted in the setting of cardiovascular disease, resulting in pathological changes at multiple levels, from subcellular cardiac signaling of neurotransmitters to extra-cardiac, extra-thoracic remodeling. The subsequent detrimental cycle of sympathovagal imbalance, characterized by sympathoexcitation and parasympathetic withdrawal, predisposes to ventricular arrhythmias, progression of heart failure, and cardiac mortality. Knowledge on the etiology and pathophysiology of this condition has increased exponentially over the past few decades, resulting in a number of different neuromodulatory approaches. However, significant knowledge gaps in both sympathetic and parasympathetic interactions and causal factors that mediate progressive sympathoexcitation and parasympathetic dysfunction remain.

Conclusions

Although our understanding of autonomic imbalance in cardiovascular diseases has significantly increased, specific, pivotal mediators of this imbalance and the recognition and implementation of available autonomic parameters and neuromodulatory therapies are still lagging.
Literatur
8.
Zurück zum Zitat Janig W (2006) Integrative action of the autonomic nervous system: neurobiology of homeostasis. Cambridge University Press, CambridgeCrossRef Janig W (2006) Integrative action of the autonomic nervous system: neurobiology of homeostasis. Cambridge University Press, CambridgeCrossRef
13.
Zurück zum Zitat Armour JA, Ardell JL (2004) Basic and clinical neurocardiology. Oxford University Press, New York Armour JA, Ardell JL (2004) Basic and clinical neurocardiology. Oxford University Press, New York
20.
Zurück zum Zitat Kirchberber MA, Tada M, Katz AM (1975) Phospholamban: a regulatory protein of the cardiac sarcoplasmic reticulum. Recent Adv Stud Cardiac Struct Metab 5:103–115PubMed Kirchberber MA, Tada M, Katz AM (1975) Phospholamban: a regulatory protein of the cardiac sarcoplasmic reticulum. Recent Adv Stud Cardiac Struct Metab 5:103–115PubMed
27.
Zurück zum Zitat Vinogradova TM, Lyashkov AE, Zhu W, Ruknudin AM, Sirenko S, Yang D, Deo S, Barlow M, Johnson S, Caffrey JL, Zhou YY, Xiao RP, Cheng H, Stern MD, Maltsev VA, Lakatta EG (2006) High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells. Circ Res 98:505–514. https://doi.org/10.1161/01.RES.0000204575.94040.d1CrossRefPubMed Vinogradova TM, Lyashkov AE, Zhu W, Ruknudin AM, Sirenko S, Yang D, Deo S, Barlow M, Johnson S, Caffrey JL, Zhou YY, Xiao RP, Cheng H, Stern MD, Maltsev VA, Lakatta EG (2006) High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells. Circ Res 98:505–514. https://​doi.​org/​10.​1161/​01.​RES.​0000204575.​94040.​d1CrossRefPubMed
31.
Zurück zum Zitat Chiamvimonvat N, Chen-Izu Y, Clancy CE, Deschenes I, Dobrev D, Heijman J, Izu L, Qu Z, Ripplinger CM, Vandenberg JI, Weiss JN, Koren G, Banyasz T, Grandi E, Sanguinetti MC, Bers DM, Nerbonne JM (2017) Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. J Physiol 595:2229–2252. https://doi.org/10.1113/JP272883CrossRefPubMedPubMedCentral Chiamvimonvat N, Chen-Izu Y, Clancy CE, Deschenes I, Dobrev D, Heijman J, Izu L, Qu Z, Ripplinger CM, Vandenberg JI, Weiss JN, Koren G, Banyasz T, Grandi E, Sanguinetti MC, Bers DM, Nerbonne JM (2017) Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. J Physiol 595:2229–2252. https://​doi.​org/​10.​1113/​JP272883CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T, Endo J, Sano M, Kawakami T, Kimura T, Monkawa T, Hayashi M, Iwanami A, Okano H, Okada Y, Ishibashi-Ueda H, Ogawa S, Fukuda K (2010) Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest 120:408–421. https://doi.org/10.1172/JCI39778CrossRefPubMedPubMedCentral Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T, Endo J, Sano M, Kawakami T, Kimura T, Monkawa T, Hayashi M, Iwanami A, Okano H, Okada Y, Ishibashi-Ueda H, Ogawa S, Fukuda K (2010) Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest 120:408–421. https://​doi.​org/​10.​1172/​JCI39778CrossRefPubMedPubMedCentral
81.
Zurück zum Zitat Gibbs T, Tapoulal N, Shanmuganathan M, Burrage MK, Borlotti A, Banning AP, Choudhury RP, Neubauer S, Kharbanda RK, Ferreira VM, Channon KM, Herring N, Ox AMIS (2022) Neuropeptide-Y levels in ST-segment-elevation myocardial infarction: relationship with coronary microvascular function, heart failure, and mortality. J Am Heart Assoc 11:e024850. https://doi.org/10.1161/JAHA.121.024850CrossRefPubMedPubMedCentral Gibbs T, Tapoulal N, Shanmuganathan M, Burrage MK, Borlotti A, Banning AP, Choudhury RP, Neubauer S, Kharbanda RK, Ferreira VM, Channon KM, Herring N, Ox AMIS (2022) Neuropeptide-Y levels in ST-segment-elevation myocardial infarction: relationship with coronary microvascular function, heart failure, and mortality. J Am Heart Assoc 11:e024850. https://​doi.​org/​10.​1161/​JAHA.​121.​024850CrossRefPubMedPubMedCentral
82.
Zurück zum Zitat Kalla M, Hao G, Tapoulal N, Tomek J, Liu K, Woodward L, Oxford Acute Myocardial Infarction S, Dall’Armellina E, Banning AP, Choudhury RP, Neubauer S, Kharbanda RK, Channon KM, Ajijola OA, Shivkumar K, Paterson DJ, Herring N (2020) The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J 41:2168–2179. https://doi.org/10.1093/eurheartj/ehz852CrossRefPubMed Kalla M, Hao G, Tapoulal N, Tomek J, Liu K, Woodward L, Oxford Acute Myocardial Infarction S, Dall’Armellina E, Banning AP, Choudhury RP, Neubauer S, Kharbanda RK, Channon KM, Ajijola OA, Shivkumar K, Paterson DJ, Herring N (2020) The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J 41:2168–2179. https://​doi.​org/​10.​1093/​eurheartj/​ehz852CrossRefPubMed
89.
Zurück zum Zitat Gardner RT, Wang L, Lang BT, Cregg JM, Dunbar CL, Woodward WR, Silver J, Ripplinger CM, Habecker BA (2015) Targeting protein tyrosine phosphatase sigma after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nat Commun 6:6235. https://doi.org/10.1038/ncomms7235CrossRefPubMed Gardner RT, Wang L, Lang BT, Cregg JM, Dunbar CL, Woodward WR, Silver J, Ripplinger CM, Habecker BA (2015) Targeting protein tyrosine phosphatase sigma after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nat Commun 6:6235. https://​doi.​org/​10.​1038/​ncomms7235CrossRefPubMed
93.
Zurück zum Zitat Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C, Pagano G, Marsico F, Lymperopoulos A, Leosco D (2012) Targeting the beta-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail 5:385–391. https://doi.org/10.1161/CIRCHEARTFAILURE.112.966895CrossRefPubMed Rengo G, Perrone-Filardi P, Femminella GD, Liccardo D, Zincarelli C, de Lucia C, Pagano G, Marsico F, Lymperopoulos A, Leosco D (2012) Targeting the beta-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail 5:385–391. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​112.​966895CrossRefPubMed
94.
Zurück zum Zitat Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1–24PubMed Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1–24PubMed
100.
Zurück zum Zitat Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB (1988) Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 247:1039–1045PubMed Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB (1988) Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 247:1039–1045PubMed
101.
Zurück zum Zitat Cohn JN (1993) The vasodilator-heart failure trials (V-HeFT). Mechanistic data from the VA cooperative studies introduction. Circulation 87:VI1-4PubMed Cohn JN (1993) The vasodilator-heart failure trials (V-HeFT). Mechanistic data from the VA cooperative studies introduction. Circulation 87:VI1-4PubMed
105.
Zurück zum Zitat Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Schalij MJ, Bax JJ (2010) Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 55:2769–2777. https://doi.org/10.1016/j.jacc.2009.12.066CrossRefPubMed Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Schalij MJ, Bax JJ (2010) Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 55:2769–2777. https://​doi.​org/​10.​1016/​j.​jacc.​2009.​12.​066CrossRefPubMed
107.
Zurück zum Zitat Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 63:141–149. https://doi.org/10.1016/j.jacc.2013.07.096CrossRefPubMed Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 63:141–149. https://​doi.​org/​10.​1016/​j.​jacc.​2013.​07.​096CrossRefPubMed
117.
124.
Zurück zum Zitat de Champlain J (1990) Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens Suppl 8:S77-85PubMed de Champlain J (1990) Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens Suppl 8:S77-85PubMed
133.
140.
Zurück zum Zitat Bohm M, Kirchmayr R, Erdmann E (1995) Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc Res 30:611–618PubMed Bohm M, Kirchmayr R, Erdmann E (1995) Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc Res 30:611–618PubMed
142.
Zurück zum Zitat Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12:451–459. https://doi.org/10.1016/s0895-7061(99)00005-9CrossRefPubMed Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12:451–459. https://​doi.​org/​10.​1016/​s0895-7061(99)00005-9CrossRefPubMed
153.
Zurück zum Zitat Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016. https://doi.org/10.1056/NEJMoa1805689CrossRefPubMed Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016. https://​doi.​org/​10.​1056/​NEJMoa1805689CrossRefPubMed
158.
Zurück zum Zitat Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E (2016) Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure association of the European society of cardiology. Eur J Heart Fail 18:8–27. https://doi.org/10.1002/ejhf.424CrossRefPubMed Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E (2016) Current state of knowledge on Takotsubo syndrome: a position statement from the taskforce on Takotsubo syndrome of the heart failure association of the European society of cardiology. Eur J Heart Fail 18:8–27. https://​doi.​org/​10.​1002/​ejhf.​424CrossRefPubMed
162.
Zurück zum Zitat Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Yh S, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C (2018) International expert consensus document on Takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 39:2032–2046. https://doi.org/10.1093/eurheartj/ehy076CrossRefPubMedPubMedCentral Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Yh S, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C (2018) International expert consensus document on Takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 39:2032–2046. https://​doi.​org/​10.​1093/​eurheartj/​ehy076CrossRefPubMedPubMedCentral
166.
Zurück zum Zitat Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O’Gara P, Stuckey DJ, Nikolaev VO, Diakonov I, Pannell L, Gong H, Sun H, Peters NS, Petrou M, Zheng Z, Gorelik J, Lyon AR, Harding SE (2012) High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 126:697–706. https://doi.org/10.1161/CIRCULATIONAHA.112.111591CrossRefPubMedPubMedCentral Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O’Gara P, Stuckey DJ, Nikolaev VO, Diakonov I, Pannell L, Gong H, Sun H, Peters NS, Petrou M, Zheng Z, Gorelik J, Lyon AR, Harding SE (2012) High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 126:697–706. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​112.​111591CrossRefPubMedPubMedCentral
167.
Zurück zum Zitat Borchert T, Hubscher D, Guessoum CI, Lam TD, Ghadri JR, Schellinger IN, Tiburcy M, Liaw NY, Li Y, Haas J, Sossalla S, Huber MA, Cyganek L, Jacobshagen C, Dressel R, Raaz U, Nikolaev VO, Guan K, Thiele H, Meder B, Wollnik B, Zimmermann WH, Luscher TF, Hasenfuss G, Templin C, Streckfuss-Bomeke K (2017) Catecholamine-dependent beta-adrenergic signaling in a pluripotent stem cell model of Takotsubo cardiomyopathy. J Am Coll Cardiol 70:975–991. https://doi.org/10.1016/j.jacc.2017.06.061CrossRefPubMed Borchert T, Hubscher D, Guessoum CI, Lam TD, Ghadri JR, Schellinger IN, Tiburcy M, Liaw NY, Li Y, Haas J, Sossalla S, Huber MA, Cyganek L, Jacobshagen C, Dressel R, Raaz U, Nikolaev VO, Guan K, Thiele H, Meder B, Wollnik B, Zimmermann WH, Luscher TF, Hasenfuss G, Templin C, Streckfuss-Bomeke K (2017) Catecholamine-dependent beta-adrenergic signaling in a pluripotent stem cell model of Takotsubo cardiomyopathy. J Am Coll Cardiol 70:975–991. https://​doi.​org/​10.​1016/​j.​jacc.​2017.​06.​061CrossRefPubMed
171.
Zurück zum Zitat Redfors B, Vedad R, Angeras O, Ramunddal T, Petursson P, Haraldsson I, Ali A, Dworeck C, Odenstedt J, Ioaness D, Libungan B, Shao Y, Albertsson P, Stone GW, Omerovic E (2015) Mortality in Takotsubo syndrome is similar to mortality in myocardial infarction—a report from the SWEDEHEART registry. Int J Cardiol 185:282–289. https://doi.org/10.1016/j.ijcard.2015.03.162CrossRefPubMed Redfors B, Vedad R, Angeras O, Ramunddal T, Petursson P, Haraldsson I, Ali A, Dworeck C, Odenstedt J, Ioaness D, Libungan B, Shao Y, Albertsson P, Stone GW, Omerovic E (2015) Mortality in Takotsubo syndrome is similar to mortality in myocardial infarction—a report from the SWEDEHEART registry. Int J Cardiol 185:282–289. https://​doi.​org/​10.​1016/​j.​ijcard.​2015.​03.​162CrossRefPubMed
172.
177.
Zurück zum Zitat Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF (2015) Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938. https://doi.org/10.1056/NEJMoa1406761CrossRefPubMed Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF (2015) Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938. https://​doi.​org/​10.​1056/​NEJMoa1406761CrossRefPubMed
183.
Zurück zum Zitat Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz PJ, Vincent GM, Benhorin J, Heilbron EL, Towbin JA, Priori SG, Napolitano C, Zhang L, Medina A, Andrews ML, Timothy K (1999) Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 84:876–879. https://doi.org/10.1016/s0002-9149(99)00458-0CrossRefPubMed Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz PJ, Vincent GM, Benhorin J, Heilbron EL, Towbin JA, Priori SG, Napolitano C, Zhang L, Medina A, Andrews ML, Timothy K (1999) Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 84:876–879. https://​doi.​org/​10.​1016/​s0002-9149(99)00458-0CrossRefPubMed
185.
Zurück zum Zitat Noda T, Takaki H, Kurita T, Suyama K, Nagaya N, Taguchi A, Aihara N, Kamakura S, Sunagawa K, Nakamura K, Ohe T, Horie M, Napolitano C, Towbin JA, Priori SG, Shimizu W (2002) Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 23:975–983. https://doi.org/10.1053/euhj.2001.3079CrossRefPubMed Noda T, Takaki H, Kurita T, Suyama K, Nagaya N, Taguchi A, Aihara N, Kamakura S, Sunagawa K, Nakamura K, Ohe T, Horie M, Napolitano C, Towbin JA, Priori SG, Shimizu W (2002) Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 23:975–983. https://​doi.​org/​10.​1053/​euhj.​2001.​3079CrossRefPubMed
187.
191.
Zurück zum Zitat Tanabe Y, Inagaki M, Kurita T, Nagaya N, Taguchi A, Suyama K, Aihara N, Kamakura S, Sunagawa K, Nakamura K, Ohe T, Towbin JA, Priori SG, Shimizu W (2001) Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 37:911–919. https://doi.org/10.1016/s0735-1097(00)01200-6CrossRefPubMed Tanabe Y, Inagaki M, Kurita T, Nagaya N, Taguchi A, Suyama K, Aihara N, Kamakura S, Sunagawa K, Nakamura K, Ohe T, Towbin JA, Priori SG, Shimizu W (2001) Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 37:911–919. https://​doi.​org/​10.​1016/​s0735-1097(00)01200-6CrossRefPubMed
197.
203.
205.
207.
Zurück zum Zitat Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378–1384. https://doi.org/10.1086/324565CrossRefPubMedPubMedCentral Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378–1384. https://​doi.​org/​10.​1086/​324565CrossRefPubMedPubMedCentral
213.
Zurück zum Zitat De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, Crotti L, Davis AM, Eldar M, Kharlap M, Khoury A, Krahn AD, Leenhardt A, Moir CR, Odero A, Olde Nordkamp L, Paul T, Roses INF, Shkolnikova M, Till J, Wilde AA, Ackerman MJ, Schwartz PJ (2015) Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 131:2185–2193. https://doi.org/10.1161/CIRCULATIONAHA.115.015731CrossRefPubMed De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, Crotti L, Davis AM, Eldar M, Kharlap M, Khoury A, Krahn AD, Leenhardt A, Moir CR, Odero A, Olde Nordkamp L, Paul T, Roses INF, Shkolnikova M, Till J, Wilde AA, Ackerman MJ, Schwartz PJ (2015) Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 131:2185–2193. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​115.​015731CrossRefPubMed
214.
216.
Zurück zum Zitat van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA (2011) Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57:2244–2254. https://doi.org/10.1016/j.jacc.2011.01.026CrossRefPubMedPubMedCentral van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA (2011) Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57:2244–2254. https://​doi.​org/​10.​1016/​j.​jacc.​2011.​01.​026CrossRefPubMedPubMedCentral
217.
Zurück zum Zitat Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, Napolitano C, Coetzee WA, Boyden PA, Priori SG (2011) Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 109:291–295. https://doi.org/10.1161/CIRCRESAHA.111.247338CrossRefPubMed Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, Napolitano C, Coetzee WA, Boyden PA, Priori SG (2011) Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 109:291–295. https://​doi.​org/​10.​1161/​CIRCRESAHA.​111.​247338CrossRefPubMed
219.
Zurück zum Zitat Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, Batra AS, Kaufman ES, Fairbrother DL, Saarel EV, Etheridge SP, Kanter RJ, Carboni MP, Dzurik MV, Fountain D, Chen H, Ely EW, Roden DM, Knollmann BC (2017) Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol 2:759–766. https://doi.org/10.1001/jamacardio.2017.1320CrossRefPubMedPubMedCentral Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, Batra AS, Kaufman ES, Fairbrother DL, Saarel EV, Etheridge SP, Kanter RJ, Carboni MP, Dzurik MV, Fountain D, Chen H, Ely EW, Roden DM, Knollmann BC (2017) Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol 2:759–766. https://​doi.​org/​10.​1001/​jamacardio.​2017.​1320CrossRefPubMedPubMedCentral
224.
Zurück zum Zitat Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93:1043–1065CrossRef Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93:1043–1065CrossRef
229.
Zurück zum Zitat Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA (1998) Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98:1510–1516. https://doi.org/10.1161/01.cir.98.15.1510CrossRefPubMed Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA (1998) Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98:1510–1516. https://​doi.​org/​10.​1161/​01.​cir.​98.​15.​1510CrossRefPubMed
242.
247.
250.
Zurück zum Zitat Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, Investigators A-H (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55:2212–2221. https://doi.org/10.1016/j.jacc.2010.01.014CrossRefPubMed Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J, Investigators A-H (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55:2212–2221. https://​doi.​org/​10.​1016/​j.​jacc.​2010.​01.​014CrossRefPubMed
251.
Zurück zum Zitat Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D et al (1992) Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477PubMed Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, Bourguignon MH, Benvenuti C, Duval AM, Agostini D et al (1992) Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477PubMed
253.
255.
Zurück zum Zitat Luisi AJ Jr, Suzuki G, Dekemp R, Haka MS, Toorongian SA, Canty JM Jr, Fallavollita JA (2005) Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 46:1368–1374PubMed Luisi AJ Jr, Suzuki G, Dekemp R, Haka MS, Toorongian SA, Canty JM Jr, Fallavollita JA (2005) Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 46:1368–1374PubMed
256.
Zurück zum Zitat Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, American College of C, American Heart A, Canadian Cardiovascular S (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44:671–719. https://doi.org/10.1016/j.jacc.2004.07.002CrossRefPubMed Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, American College of C, American Heart A, Canadian Cardiovascular S (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44:671–719. https://​doi.​org/​10.​1016/​j.​jacc.​2004.​07.​002CrossRefPubMed
257.
Zurück zum Zitat Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:1757–1780. https://doi.org/10.1016/j.jacc.2021.12.011CrossRefPubMed Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:1757–1780. https://​doi.​org/​10.​1016/​j.​jacc.​2021.​12.​011CrossRefPubMed
258.
Zurück zum Zitat CIBIS Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13CrossRef CIBIS Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13CrossRef
259.
Zurück zum Zitat MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007CrossRef MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007CrossRef
265.
Zurück zum Zitat Peach MJ, Bumpus FM, Khairallah PA (1969) Inhibition of norepinephrine uptake in hearts by angiotensin II and analogs. J Pharmacol Exp Ther 167:291–299PubMed Peach MJ, Bumpus FM, Khairallah PA (1969) Inhibition of norepinephrine uptake in hearts by angiotensin II and analogs. J Pharmacol Exp Ther 167:291–299PubMed
274.
Zurück zum Zitat Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H (1997) ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38:1085–1089PubMed Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H (1997) ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38:1085–1089PubMed
275.
Zurück zum Zitat Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan O, Dukat A, Lefkowitz MP, McMurray JJ (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail 9:e002744. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002744CrossRefPubMed Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan O, Dukat A, Lefkowitz MP, McMurray JJ (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail 9:e002744. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​115.​002744CrossRefPubMed
276.
Zurück zum Zitat Boehmer AA, Schubert T, von Stuelpnagel L, Bauer A, Dobre B, Kaess BM, Ehrlich JR (2022) Abstract 13303: influence of ARNI on cardiac autonomic nervous system. Circulation 146:A13303CrossRef Boehmer AA, Schubert T, von Stuelpnagel L, Bauer A, Dobre B, Kaess BM, Ehrlich JR (2022) Abstract 13303: influence of ARNI on cardiac autonomic nervous system. Circulation 146:A13303CrossRef
279.
Zurück zum Zitat Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J, investigators Et (2020) Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 19:148. https://doi.org/10.1186/s12933-020-01127-zCrossRefPubMedPubMedCentral Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y, Yodogawa K, Iwasaki YK, Yamamoto T, Takano H, Tsukada Y, Asai K, Miyamoto M, Miyauchi Y, Kodani E, Ishikawa M, Maruyama M, Ogano M, Tanabe J, investigators Et (2020) Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol 19:148. https://​doi.​org/​10.​1186/​s12933-020-01127-zCrossRefPubMedPubMedCentral
282.
288.
Zurück zum Zitat Dusi V, Gornbein J, Do DH, Sorg JM, Khakpour H, Krokhaleva Y, Ajijola OA, Macias C, Bradfield JS, Buch E, Fujimura OA, Boyle NG, Yanagawa J, Lee JM, Shivkumar K, Vaseghi M (2021) Arrhythmic risk profile and outcomes of patients undergoing cardiac sympathetic denervation for recurrent monomorphic ventricular tachycardia after ablation. J Am Heart Assoc 10:e018371. https://doi.org/10.1161/JAHA.120.018371CrossRefPubMedPubMedCentral Dusi V, Gornbein J, Do DH, Sorg JM, Khakpour H, Krokhaleva Y, Ajijola OA, Macias C, Bradfield JS, Buch E, Fujimura OA, Boyle NG, Yanagawa J, Lee JM, Shivkumar K, Vaseghi M (2021) Arrhythmic risk profile and outcomes of patients undergoing cardiac sympathetic denervation for recurrent monomorphic ventricular tachycardia after ablation. J Am Heart Assoc 10:e018371. https://​doi.​org/​10.​1161/​JAHA.​120.​018371CrossRefPubMedPubMedCentral
289.
Zurück zum Zitat Conceicao-Souza GE, Pego-Fernandes PM, Cruz F, Guimaraes GV, Bacal F, Vieira ML, Grupi CJ, Giorgi MC, Consolim-Colombo FM, Negrao CE, Rondon MU, Moreira LF, Bocchi EA (2012) Left cardiac sympathetic denervation for treatment of symptomatic systolic heart failure patients: a pilot study. Eur J Heart Fail 14:1366–1373. https://doi.org/10.1093/eurjhf/hfs132CrossRefPubMed Conceicao-Souza GE, Pego-Fernandes PM, Cruz F, Guimaraes GV, Bacal F, Vieira ML, Grupi CJ, Giorgi MC, Consolim-Colombo FM, Negrao CE, Rondon MU, Moreira LF, Bocchi EA (2012) Left cardiac sympathetic denervation for treatment of symptomatic systolic heart failure patients: a pilot study. Eur J Heart Fail 14:1366–1373. https://​doi.​org/​10.​1093/​eurjhf/​hfs132CrossRefPubMed
291.
Zurück zum Zitat Waddell-Smith KE, Ertresvaag KN, Li J, Chaudhuri K, Crawford JR, Hamill JK, Haydock D, Skinner JR, Cardiac Inherited Disease Group New Z (2015) Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 8:1151–1158. https://doi.org/10.1161/CIRCEP.115.003159CrossRefPubMed Waddell-Smith KE, Ertresvaag KN, Li J, Chaudhuri K, Crawford JR, Hamill JK, Haydock D, Skinner JR, Cardiac Inherited Disease Group New Z (2015) Physical and psychological consequences of left cardiac sympathetic denervation in long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 8:1151–1158. https://​doi.​org/​10.​1161/​CIRCEP.​115.​003159CrossRefPubMed
292.
Zurück zum Zitat Cha YM, Li X, Yang M, Han J, Wu G, Kapa SC, McLeod CJ, Noseworthy PA, Mulpuru SK, Asirvatham SJ, Brady PA, Rho RH, Friedman PA, Lee HC, Tian Y, Zhou S, Munger TM, Ackerman MJ, Shen WK (2019) Stellate ganglion block and cardiac sympathetic denervation in patients with inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 30:2920–2928. https://doi.org/10.1111/jce.14233CrossRefPubMedPubMedCentral Cha YM, Li X, Yang M, Han J, Wu G, Kapa SC, McLeod CJ, Noseworthy PA, Mulpuru SK, Asirvatham SJ, Brady PA, Rho RH, Friedman PA, Lee HC, Tian Y, Zhou S, Munger TM, Ackerman MJ, Shen WK (2019) Stellate ganglion block and cardiac sympathetic denervation in patients with inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 30:2920–2928. https://​doi.​org/​10.​1111/​jce.​14233CrossRefPubMedPubMedCentral
304.
Zurück zum Zitat Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401. https://doi.org/10.1056/NEJMoa1402670CrossRefPubMed Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401. https://​doi.​org/​10.​1056/​NEJMoa1402670CrossRefPubMed
305.
Zurück zum Zitat Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D’Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, Investigators SH-OMP (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451. https://doi.org/10.1016/S0140-6736(20)30554-7CrossRefPubMed Bohm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D’Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, Investigators SH-OMP (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 395:1444–1451. https://​doi.​org/​10.​1016/​S0140-6736(20)30554-7CrossRefPubMed
306.
Zurück zum Zitat Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, Investigators SH-OMT (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391:2346–2355. https://doi.org/10.1016/S0140-6736(18)30951-6CrossRefPubMed Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, Investigators SH-OMT (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 391:2346–2355. https://​doi.​org/​10.​1016/​S0140-6736(18)30951-6CrossRefPubMed
307.
Zurück zum Zitat Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Bohm M (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390:2160–2170. https://doi.org/10.1016/S0140-6736(17)32281-XCrossRefPubMed Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Bohm M (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390:2160–2170. https://​doi.​org/​10.​1016/​S0140-6736(17)32281-XCrossRefPubMed
315.
322.
325.
Zurück zum Zitat Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D’Onofrio A, Solomon SD, Wold N, Ruble SB (2015) Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 36:425–433. https://doi.org/10.1093/eurheartj/ehu345CrossRefPubMed Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D’Onofrio A, Solomon SD, Wold N, Ruble SB (2015) Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 36:425–433. https://​doi.​org/​10.​1093/​eurheartj/​ehu345CrossRefPubMed
Metadaten
Titel
Autonomic control of ventricular function in health and disease: current state of the art
verfasst von
Valerie Y. H. van Weperen
Crystal M. Ripplinger
Marmar Vaseghi
Publikationsdatum
11.05.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Autonomic Research / Ausgabe 4/2023
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-023-00948-8

Weitere Artikel der Ausgabe 4/2023

Clinical Autonomic Research 4/2023 Zur Ausgabe